Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET

Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of Poor Ovarian Response (POR) Clinical Outcome in Patients Undergoing in Vitro Fertilization / Embryo Transfer (IVF/ET)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02801591

Enrollment

240

Registered

2016-06-16

Start date

2016-02-29

Completion date

Unknown

Last updated

2016-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor Ovarian Response

Brief summary

Observe the clinical efficacy and safety of Recombinant Human Growth Hormone Injection assisted in the treatment of the patients with poor ovarian response in vitro fertilization and embryo transfer.

Interventions

PROCEDUREConventional ovarian stimulation proctol without rhGH

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 42 Years

Healthy volunteers

Inclusion criteria

* Female, age 30-42 years old. * Diagnosis of POR (2011 ESHRE Bologna Standard). * At least two previous IVF failure history. * Voluntarily to sign the informed consent.

Exclusion criteria

* Severe acute and chronic liver and kidney disease，Such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity period, etc.；Liver and kidney dysfunction. * Endocrine and metabolic diseases，eg, diabetes、Thyroid function hyperthyroidism, Thyroid dysfunction, cushing's syndrome, hyperprolactinemia，hyperandrogenism. * Related diseases affecting outcome of IVF pregnancy，eg, hydrosalpinx, hysteromyoma≥4cm, adenomyosis, stage III and IV endometriosis, untreated endometrial lesions, uterine malformation, genital tuberculosis, malignant tumor of reproductive system （include endometrial carcinoma, cervical carcinoma, ovarian cancer, fallopian tube carcinoma）. * Allergic to E. coli expression product and its excipients. * Subjects who participated in the past three months or are participating in other drug clinical researchers. * IVF failure history≥3. * The researchers consider who is not suitable for enrolling the group.

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate	One year

Secondary

Measure	Time frame
Number of retrieved oocytes	One year
Number of high quality embryos	One year
Number of embryos transferred	One year

Countries

China

Contacts

Primary ContactRui Yang

010-82265080

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026